Search results
Aptamer Group up 12% on AstraZeneca collaboration
Proactive Financial News· 17 hours agoShares of Aptamer Group PLC (AIM:APTA) were up 12% after announcing a new collaboration with AstraZeneca PLC (LSE:AZN) to explore the use of Optimer...
AstraZeneca (AZN) Imfinzi Combo Gets CHMP Nod for Expanded Use
Zacks via Yahoo Finance UK· 1 day agoThe CHMP recommends approval of AstraZeneca's (AZN) Imfinzi plus Lynparza for treating primary...
Inhaler start-up bolsters board with pharma experience
Business Insider via Yahoo News UK· 13 hours agoJane Gaddum, formerly vice president for emerging brands for AstraZeneca, has joined as chair and...
AstraZeneca endometrial cancer treatment recommended for EU approval
ShareCast· 3 days agoAstraZeneca announced on Monday that ‘Imfinzi’, or durvalumab, and ‘Lynparza’, or olaparib, have...
UK less ready for next pandemic than before Covid – Oxford vaccinologist
CityAM via Yahoo Finance UK· 13 hours agoThe UK's state apparatus is less prepared to deal with a pandemic today than it was before Covid,...
AstraZeneca's COVID-19 Prevention Drug For Patients With Weak Immune Systems - European Medicines...
Benzinga via Yahoo Finance UK· 2 days agoThe European Medicines Agency (EMA) has accepted AstraZeneca Plc's (NASDAQ:AZN) marketing...
AstraZeneca's COVID prevention drug application gets EU fast-track assessment
Reuters· 3 days ago, opens new tab said on Monday that the European Union drug regulator has accepted a market...
Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term
Zacks via Yahoo Finance UK· 5 days agoThis Score examines things like projected and historical earnings, sales, and cash flow to find...
Is GSK's share price a brilliant bargain after this new vaccines deal?
Motley Fool UK· 10 hours agoIt’s been a tough few weeks for the GSK (LSE:GSK) share price. At £15.03 per share, the FTSE 100...
Pharma Stock Roundup: FDA's CRL to MRK & ABBV, Phase III Study Failures for NVO, AZN
Zacks via Yahoo Finance UK· 5 days agoThis week, the FDA rejected Merck's MRK and AbbVie’s ABBV regulatory filings seeking approvals for...